196 related articles for article (PubMed ID: 14739059)
21. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma.
Avall-Lundqvist EH; Sjövall K; Nilsson BR; Eneroth PH
Eur J Cancer; 1992; 28A(10):1695-702. PubMed ID: 1389488
[TBL] [Abstract][Full Text] [Related]
23. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
[TBL] [Abstract][Full Text] [Related]
25. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
Scambia G; Benedetti Panici P; Perrone L; Sonsini C; Giannelli S; Gallo A; Natali PG; Mancuso S
Br J Cancer; 1990 Jul; 62(1):147-51. PubMed ID: 2167724
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluations of a new ovarian cancer marker, COX-1.
Lee G; Ng HT
Int J Gynaecol Obstet; 1995 Jul; 49 Suppl():S27-32. PubMed ID: 7589737
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma.
Chen P; Jiao L; Ren F; Wang DB
BMC Cancer; 2020 May; 20(1):423. PubMed ID: 32410650
[TBL] [Abstract][Full Text] [Related]
29. [Metastatic mechanisms of uterine malignancies and therapeutic consequences].
Lax SF; Tamussino KF; Lang PF
Pathologe; 2016 Nov; 37(6):549-556. PubMed ID: 27757531
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.
Tabata T; Takeshima N; Tanaka N; Hirai Y; Hasumi K
Tumour Biol; 2000; 21(6):375-80. PubMed ID: 11006578
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of serum growth-regulated oncogene alpha (GROalpha) in patients with gynecological cancer.
Nishikawa R; Suzumori N; Nishiyama T; Nishikawa H; Arakawa A; Sugiura-Ogasawara M
Eur J Gynaecol Oncol; 2012; 33(2):138-41. PubMed ID: 22611950
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
[TBL] [Abstract][Full Text] [Related]
34. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer.
Porika M; Tippani R; Mohammad A; Bollam SR; Panuganti SD; Abbagani S
Int J Biol Markers; 2011; 26(1):22-6. PubMed ID: 21319134
[TBL] [Abstract][Full Text] [Related]
36. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
37. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
[TBL] [Abstract][Full Text] [Related]
38. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
39. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
40. Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer.
Baser E; Togrul C; Ozgu E; Ayhan S; Caglar M; Erkaya S; Gungor T
Asian Pac J Cancer Prev; 2013; 14(12):7635-8. PubMed ID: 24460345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
